- Home
- ARAI vs BTAI Comparison
ARAI vs BTAI Comparison
Compare ARAI & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARAI | BTAI |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 35.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ARAI | BTAI |
|---|---|---|
| Price | $0.73 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $12.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 20.3M | 1.0M |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $800.66 | $197.82 |
| Revenue Next Year | $650.00 | $910.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $1.01 |
| 52 Week High | $15.50 | $8.08 |
Technical Indicators
Market Signals| Indicator | ARAI | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 36.89 |
| Support Level | $0.51 | N/A |
| Resistance Level | $1.13 | $1.26 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 17.17 | 24.49 |
Price Performance
Historical ComparisonAbout ARAI Arrive AI Inc.
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advanced chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.